Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesPulse Biosciences Inc

Pulse Biosciences Inc

Healthcare Medical Instruments & Supplies
PortfolioPortfolio WatchlistWatchlist
Company price
56.39 USD 3.10 ( 5.82%)
Last update at 2026-11-09T15:37:00Z
VOLUME
88569
Market Cap
3937.01M

Momentum Score

…

Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. It offers nPulse System, a novel Nanosecond Pulsed-Field Ablation delivery platform to treat benign lesions of the skin; nPulse Vybrance Percutaneous Electrode system for soft tissue ablation in surgical setting; nPulse Cardiac Surgical Clamp designed for use in surgical treatment of atrial fibrillation (AF); nPulse Cardiac Catheter System designed to provide a circumferential, or circular, ablation in a single treatment cycle; and nPulse Console, a software-enabled console-based platform designed to accommodate the clinical workflow preferred by physicians. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. Pulse Biosciences, Inc. was incorporated in 2014 and is headquartered in Miami, Florida.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
53.36
Low
58.94
High
52 Week Price Range
12.56
Low
58.90
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Pulse Biosciences develops Nano-Pulse Stimulation (NPS) technology and the CellFX system for dermatology and aesthetic procedures while exploring oncology and other clinical applications. Long-term growth may be driven by clinical adoption of CellFX, regulatory clearances, geographic expansion and partnerships that could support commercialization.

Principal risks are limited commercial traction so far, execution and financing needs for scaling, regulatory and reimbursement uncertainty, and competition from established device makers.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
53.29
Dividend Yield
-
Revenue TTM
1.19M
Revenue Per Share
0.02
Gross Profit TTM
0.00M
Debt / Equity
0.09
ROE
-78.49%
Net Debt
-73.20M
ROCE
-82.53%
Diluted EPS TTM
-1.19

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -72.78M -53.59M -42.21M -58.51M -63.66M
Net income -72.78M -53.59M -42.21M -58.95M -63.16M
Selling general administrative 32.03M 23.92M 15.78M 13.96M 19.07M
Selling and marketing expenses - - 1.21M 12.02M 14.75M
Gross profit -1.26M -1.18M -1.21M -11.24M -0.55M
Reconciled depreciation 1.07M 1.18M 1.24M 1.35M 1.15M
Ebit -72.78M -53.59M -41.11M -59.41M -64.16M
Ebitda -71.71M -52.41M -39.90M -58.06M -63.01M
Depreciation and amortization 1.07M 1.18M 1.21M 1.35M 1.15M
Operating income -76.94M -56.26M -43.57M -58.06M -63.01M
Other operating expenses 77.29M 56.26M 43.57M 58.76M 64.43M
Interest expense - - 1.10M 0.45M 0.65M
Tax provision - 0.00M 0.00M 0.00M 0.00M
Interest income 4.21M 2.69M - - -
Net interest income 4.21M 2.67M 0.31M -0.45M -0.65M
Income tax expense - -53.59M - 0.45M -0.50M
Total revenue 0.35M 0.00M -0.01M 0.70M 1.42M
Total operating expenses 75.68M 56.26M 42.37M 46.81M 62.46M
Cost of revenue 1.61M 1.18M 1.21M 11.94M 1.97M
Total other income expense net 4.16M 2.67M 1.36M -0.45M -0.65M
Net income from continuing ops -72.78M -53.59M -39.47M -58.51M -63.66M
Net income applicable to common shares - - - - -63.66M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 96.11M 132.46M 60.80M 77.88M 54.25M
Intangible assets 0.57M 1.22M 1.89M 2.55M 3.22M
Other current assets 2.28M 1.41M 0.96M 1.01M 2.13M
Total liab 15.46M 17.60M 16.44M 80.12M 18.56M
Total stockholder equity 80.66M 114.86M 44.36M -2.25M 35.69M
Other current liab 3.58M 7.03M 3.81M 2.60M 4.39M
Common stock 0.07M 0.07M 0.06M 0.04M 0.03M
Capital stock 0.07M 0.07M 0.06M 0.04M 0.03M
Retained earnings -463.28M -390.50M -336.92M -294.70M -236.20M
Good will 2.79M 2.79M 2.79M 2.79M 2.79M
Other assets - - - - 0.36M
Cash 80.73M 118.04M 44.37M 61.14M 28.61M
Total current liabilities 7.92M 10.05M 6.71M 5.98M 8.52M
Current deferred revenue - - - - 0.02M
Net debt -73.20M -109.14M -35.22M 14.82M -17.36M
Short term debt 1.57M 1.35M 1.06M 1.81M 1.21M
Short long term debt - - - 0.92M 0.44M
Short long term debt total 7.53M 8.90M 9.14M 75.96M 11.25M
Other stockholder equity 543.87M 505.30M 381.22M 292.42M 271.86M
Property plant equipment - - - - 11.25M
Total current assets 83.42M 119.45M 45.33M 62.15M 36.63M
Net tangible assets - - - - 29.68M
Short term investments - - - - 0.00M
Net receivables 0.27M 0.00M - 0.00M 0.06M
Long term debt - - - 65.00M -
Inventory 0.14M 0.00M - 0.00M 5.82M
Accounts payable 2.78M 1.67M 1.84M 1.57M 2.90M
Non currrent assets other 0.69M 0.68M 0.36M 0.36M 0.36M
Non current assets total 12.69M 13.01M 15.48M 15.73M 17.62M
Capital lease obligations 7.53M 8.90M 9.14M 10.04M 10.81M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments - -0.12M -0.12M -0.40M 7.56M
Change to liabilities - - - - 1.18M
Total cashflows from investing activities -0.34M -0.12M -0.12M - 7.56M
Net borrowings - - 0.00M - 0.41M
Total cash from financing activities 17.15M 110.14M 16.39M 79.94M 62.69M
Change to operating activities - - - - -1.49M
Net income -72.78M -53.59M -42.21M -58.51M -63.66M
Change in cash -37.30M 73.67M -16.77M 32.52M 16.15M
Begin period cash flow 118.04M 44.37M 61.14M 28.61M 12.46M
End period cash flow 80.73M 118.04M 44.37M 61.14M 28.61M
Total cash from operating activities -54.12M -36.34M -33.04M -47.01M -54.10M
Issuance of capital stock 0.00M 59.65M -0.03M 14.86M 56.70M
Depreciation 1.07M 1.18M 1.21M 1.35M 1.15M
Other cashflows from investing activities -0.02M - - - -
Dividends paid - - - - -0.81M
Change to inventory -0.14M 0.00M -0.36M -2.65M -5.82M
Change to account receivables -0.27M 0.05M 0.11M 0.06M -0.06M
Sale purchase of stock 0.59M 0.48M 0.40M 0.49M 0.81M
Other cashflows from financing activities 17.15M 50.49M -0.01M 65.03M 7.52M
Change to netincome - - - - 14.61M
Capital expenditures 0.32M 0.12M 0.12M 0.40M 0.44M
Change in working capital -5.02M 2.47M 0.77M -3.72M -6.20M
Stock based compensation 21.46M 13.59M 7.18M 5.19M 14.60M
Other non cash items 1.15M 0.01M 0.01M 8.66M 0.01M
Free cash flow -54.44M -36.47M -33.16M -47.41M -54.53M

Peer Comparison*

Sector: Healthcare Industry: Medical Instruments & Supplies

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
PLSE
Pulse Biosciences Inc		 3.10
5.82%		 56.39 - - 3322.37 38.84 3180.94 -1.81
ISRG
Intuitive Surgical Inc		 5.32
1.17%		 458.12 43.30 31.35 12.25 7.35 11.63 30.22
ESLOF
EssilorLuxottica Société anonyme		 2.75
1.29%		 215.85 44.84 27.62 4.07 2.49 3.71 16.04
ESLOY
Essilor International SA		 -0.44
0.41%		 107.31 41.68 27.25 3.94 2.45 3.71 16.04
BDX
Becton Dickinson and Company		 0.08
0.04%		 211.96 31.62 13.76 2.25 2.04 2.93 13.40

Profile*

Pulse Biosciences Inc

Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. It offers nPulse System, a novel Nanosecond Pulsed-Field Ablation delivery platform to treat benign lesions of the skin; nPulse Vybrance Percutaneous Electrode system for soft tissue ablation in surgical setting; nPulse Cardiac Surgical Clamp designed for use in surgical treatment of atrial fibrillation (AF); nPulse Cardiac Catheter System designed to provide a circumferential, or circular, ablation in a single treatment cycle; and nPulse Console, a software-enabled console-based platform designed to accommodate the clinical workflow preferred by physicians. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. Pulse Biosciences, Inc. was incorporated in 2014 and is headquartered in Miami, Florida.

601 Brickell Key Drive, Miami, FL, United States, 33131

510 906 4600

https://www.pulsebiosciences.com

116

Name Title Year Born
Mr. Robert W. Duggan Exec. Chairman 1944
Mr. Darrin R. Uecker CTO & Director 1966
Mr. Mitchell E. Levinson Chief Strategy Officer & Director 1960
Mr. Kevin Danahy Pres & CEO 1971
Dr. Richard Nuccitelli Ph.D. Chief Science Officer NA
Mr. Kenneth B. Stratton Esq., J.D. Gen. Counsel & Corp. Sec. 1969
Dr. Holly Hartman J.D., Ph.D. VP of Bus. Devel. & Corp. Strategy NA
Ms. Patty Perla VP of HR NA
Mr. David Danitz Sr. VP of Engineering NA
Mr. Robert W. Duggan Executive Chairman 1945

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

GFR
CAD 10.96
+38.15%
MOON
CAD 4.83
+9.64%
PDN
CAD 8.13
+7.68%
BDT
CAD 72.82
+6.65%
HG
CAD 4.28
+6.20%
CSU
CAD 3300.00
-6.42%
CURA
CAD 12.68
-4.16%
DIV
CAD 3.93
-3.44%
SOIL
CAD 7.18
-3.10%
OBE
CAD 13.31
-2.92%

Equity Sectors*

  • Basic Materials

    +3.63%

  • Communication Services

    -1.14%

  • Consumer Cyclical

    +0.75%

  • Consumer Defensive

    -0.36%

  • Energy

    +2.18%

  • Financial Services

    +1.33%

  • Healthcare

    +1.49%

  • Industrials

    +2.99%

  • Real Estate

    +0.41%

  • Technology

    +1.45%

  • Utilities

    +1.09%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…